PMID- 18041455
OWN - NLM
STAT- MEDLINE
DCOM- 20080118
LR  - 20151119
IS  - 1526-744X (Print)
IS  - 1526-744X (Linking)
VI  - 34
IP  - 5
DP  - 2007 Sep-Oct
TI  - Route of administration for erythropoiesis-stimulating agents: patient and 
      nursing considerations.
PG  - 527-31
AB  - Several clinical studies have indicated that compared with intravenous (IV) 
      administration, subcutaneous (SC) administration of Epoetin alfa may result in a 
      dose-sparing effect in patients on hemodialysis. However, data also indicate wide 
      inter-patient variability in response, with many patients requiring the same or a 
      higher dose following conversion to SC administration. Convenience favors IV 
      administration of Epoetin alfa in patients on hemodialysis, and patient 
      preferences and comfort should also be primary considerations. For patients who 
      prefer SC injections, the nurse's coordination of the required dosing, 
      administration, and operational factors is key to maintaining and improving 
      anemia-related outcomes.
FAU - Holloway, Maggie
AU  - Holloway M
AD  - Department of Pediatrics, Division of Pediatric Nephrology, University of 
      California, Los Angeles, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Nephrol Nurs J
JT  - Nephrology nursing journal : journal of the American Nephrology Nurses' 
      Association
JID - 100909377
RN  - 0 (Hematinics)
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
RN  - 64FS3BFH5W (Epoetin Alfa)
MH  - Anemia/*drug therapy/etiology/psychology
MH  - Choice Behavior
MH  - Clinical Nursing Research
MH  - Drug Administration Routes
MH  - Drug Administration Schedule
MH  - Drug Monitoring
MH  - Epoetin Alfa
MH  - Erythropoietin/*administration & dosage
MH  - Hematinics/*administration & dosage
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections, Subcutaneous
MH  - Kidney Failure, Chronic/complications
MH  - Nursing Assessment
MH  - Patient Participation
MH  - Patient Selection
MH  - Recombinant Proteins
MH  - Renal Dialysis/adverse effects/nursing/psychology
MH  - Research Design
MH  - Treatment Outcome
RF  - 18
EDAT- 2007/11/29 09:00
MHDA- 2008/01/19 09:00
CRDT- 2007/11/29 09:00
PHST- 2007/11/29 09:00 [pubmed]
PHST- 2008/01/19 09:00 [medline]
PHST- 2007/11/29 09:00 [entrez]
PST - ppublish
SO  - Nephrol Nurs J. 2007 Sep-Oct;34(5):527-31.